Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 2.1. It has been cited 77 times, with 74 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.654
From this paper's citation signal
Citation Network Contribution
1.4
From 67 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 74 citers.
Merck Sharpe & Dohme
Trans-NIH Center for Human Immunology.
National Heart, Lung, and Blood Institute
MeSH Terms
Keywords